SEC Form 4 · accession 0000886163-16-000233
LIGAND PHARMACEUTICALS INC · LGND
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Todd C Davis
Director
Period of report
Oct 31, 2016
Accepted (ET)
Nov 1, 2016 · 8:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000886163
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 31, 2016 | M | 3,333 | $53.34 | A | 59,542 | D | |
| Common Stock | Oct 31, 2016 | M | 7,335 | $32.30 | A | 66,877 | D | |
| Common Stock | Oct 31, 2016 | M | 3,312 | $67.53 | A | 70,189 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F1 | $32.30 | Oct 31, 2016 | M | 7,335 | D | — | Jun 11, 2023 | Common Stock | 7,335 | 0 | D |
| Non-Qualified Stock Option (right to buy) | $53.34 | Oct 31, 2016 | M | 3,333 | D | Mar 1, 2008 | Mar 1, 2017 | Common Stock | 3,333 | 0 | D |
| Non-Qualified Stock Option (right to buy)F2 | $67.53 | Oct 31, 2016 | M | 3,312 | D | — | Jun 4, 2024 | Common Stock | 3,312 | 0 | D |
Explanation of responses
- F1Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 11, 2013, and will fully vest on the first anniversary of the grant date.
- F2Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 04, 2014. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.